



Supplementary Materials: Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

Apriliana Cahya Khayrani¹, Hafizah Mahmud¹, Aung Ko Ko Oo¹, Maram H. Zahra², Miharu Oze¹, Juan Du¹, Md Jahangir Alam¹, Said M Afify¹, Tsukasa Shigehiro^{1,3}, Anna Sanchez Calle⁴, Akimasa Seno², Hiroki Hamada⁵, Yuhki Seno^{6,7}, Tadakatsu Mandai⁷, Masaharu Seno^{1,2*}

Table S1. List of primers used in the experiments.

No	Names	Forward primer Sequence (5'→3')	Reverse primer Sequence (5'→3')
1	CD44s	TGGGTCATAGAAGGGCACG	AGGTGGAGCTGAAGCATTGAA
2	GAPDH	CAACGACCACTTTGTCAAGCTC	GGTCTACATGGCAACTGTGAGG




Figure S1. Anti-hCD44 MAb preparation. (A) Western blot result of conditioned medium of HB-9480 cells culture for 0 to 10 days detected by goat anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc., CA, USA), 100 ng of Mouse IgG as positive control. (B) CBB staining of SDS PAGE of anti-hCD44 MAb eluted from protein A column.




Figure S2. Dot blotting analysis of liposomes conjugated to ligands. Liposomes containing approximately 6 μg of gPTX in 2 μL were blotted onto PVDF membrane and probed with peroxidase-labelled Protein A (KPL, USA) (red dashed circle indicate the positions of dots). The immunoreactivity indicates that anti-hCD44 MAb was conjugated to liposome.




Figure S3. Drug sensitivity evaluation of SK-OV-3 cells (A, B) and OVK18 cells (C,D) after 72 hours drug exposure (closed circle is MTT reagent directly added after drug treatment, closed square is MTT added after 48 hours drug replaced by fresh medium). (A, C) Cells were treated with PTX. (B, D) Cells were treated with gPTX.

